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Summary
Background: In the Netherlands, 45% of all cancer cases 
occur in men and women aged 70 years and older. Since the 
population is ageing and cancer incidence rises with age, the 
number of new malignancies in the elderly is increasing. It 
has become apparent that there is a relationship between age 
at diagnosis and the treatment received. Therefore, age-spe­
cific variations in patterns of care for six common forms of 
cancer in the elderly, are examined.
Patients and methods: Patients aged 50 years and older, 
diagnosed in the period 1988-1992 in Middle and South 
Limburg with breast, colorectal, lung, ovarian, head and neck 
cancer and non-Hodgkin lymphoma were included (n “  
6911). Data were obtained from the population-based Re­
gional Cancer Registry of the Comprehensive Cancer Centre 
Limburg. Age-specific differences in diagnostics and treat­
ment were analysed using chi-square analysis (age categories: 
50-59, 60-69, 70+). Logistic regression analyses were used 
to examine the extent to which age increased the chance of 
not being treated or of receiving less intensive treatment, 
while controlling for the stage of the disease and the sex of 
the patient.
Results: For all malignancies the stage was unknown in a 
larger proportion of the patients aged 70 years and older 
than in the younger patient groups. Compared to their
younger counterparts, the diagnosis of elderly breast, colo­
rectal and lung cancer patients was more often based solely 
on clinical grounds. In the total study population, 16% were 
not treated, Per age category 50-59 years, 60-69 years and 
704- these percentages were 7%, 12% and 22%, respectively, 
(P-trend = 0.001). For all malignancies the chance of not re­
ceiving treatment increased with increasing age. However, the 
size and nature of the differences varied with the localisation 
of the tumour. The proportion of untreated patients was par­
ticularly high in the patients with lung cancer and metastatic 
colorectal and ovarian cancer, and there was an increase with 
increasing age (P-trend = 0.001). The vast majority of pa­
tients with NHL, breast, head and neck and non-metastatic 
colorectal cancer received treatment, 90%, 94%, 91%, and 
99%, respectively, However, elderly patients less often re­
ceived a combination of treatment modalities.
Conclusiom: The diagnostics and choice of treatment for 
several common types of cancer were dependent on age. This 
study could not take into account the major problem of co­
morbidity which can be a reason to choose for lesser therapy 
in the elderly. More research is necessary to determine which 
factors determine the diagnostics and choice of treatment 
and whether these factors differ between young and elderly 
patients.
Key words: cancer, elderly, patterns of care
Introduction selected on the grounds of not having any coniorhid
conditions.
Steady increases in the survival length of cancer pa- Existing literature gives the impression, that a greater
tients and of life expectancy as such in the Netherlands proportion of elderly patients are not treated or receive 
are expected to lead to an increase in the prevalence of less intensive treatment (e.g., in terms of monotherapy
cancer. At present, over 45% of incident cancer pa- versus combination therapy) than younger patients [4-
tients in the Netherlands are older than 70 years at 11], In addition, there is hesitance about administering
diagnosis [1]. Very little knowledge is available on the chemotherapy to elderly patients and, not infrequently,
course of disease in the elderly, or more importantly, on a potentially curative operation is not performed be-
specific treatment policies for elderly cancer patients, cause the risk is assumed to be too high [12-15]. It is
Knowledge about treatment methods is mainly based not the elderly patients themselves who choose less
on experience with patients younger than 70 years, intensive treatment, although for them toxicity and
Clinical trials often apply the same age limit [2, 3]. In quality of life do weigh more heavily [16]. A  survey by
the few studies that included elderly patients, they were telephone revealed that treating physicians were less in-
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clined to offer alternative treatment modalities to 
elderly patients [17].
We performed a study on the differences in diagnos­
tics and treatment between young and elderly cancer 
patients in the Middle and Southern part of the prov­
ince of Limburg. The study group comprised patients 
with several common forms of cancer: breast, colorec­
tal, lung, ovarian, head and neck cancer and non- 
Hodgkin lymphoma. Besides the high incidence of 
these common tumours, variation in treatment modal­
ities was a basis for selection.
Patients and methods
Data collection
Data on incident cancer cases and data on diagnostic procedures 
and treatment were obtained from the Regional Cancer Registry 
Limburg, a department of the Comprehensive Cancer Centre Lim­
burg (IKL). This population-based Cancer Registry covers the 
regions of M iddle and South Limburg with about 850,000 inhabi­
tants and 8 hospitals (for a description of the region and registration 
procedures see [18]).
Study population
Patients aged 50 years and older who were diagnosed between 1 
January 1988 and 31 December 1992 with breast cancer (n - 
1637), colorectal cancer (n = 1935), lung cancer (n «  2341), ovarian 
cancer (n =  255), head and neck cancer (n - 412) or a non-Hodgkin 
lymphoma (n = 331) were included in the study (total n - 6911). We 
excluded patients who had had an earlier malignancy and those in 
whom the diagnosis had not been made until autopsy.
Definitions and operationnlis Alton 
Age
The patients were divided into three age categories: 50-59 years, 
60-69 years and 70 years and olden
Tumour stage
In the IKL-registry tumour stage is registered according to the TNM 
classification system, the Ann Arbor staging system for lymphomas 
and the FI G O  classification system for gynaecological tumours [19]. 
Tumour stage referred to the extent of the disease at the time of 
making the definitive decision about the treatment policy. For the 
current study, the simplified staging system was used: stage 1, 2 , 3, or
4 and stage unknown. For the analysis of treatment by age, various 
stages were grouped together on the basis of similarities in general 
treatment modalities (see Table 1).
Grade of m alignancy
Owing to the fact that in non-Hodgkin lymphoma more than in any 
other malignancy, classification according to malignancy grade plays 
a major role in determining the choice of treatment and the prog­
nosis [20], this factor was also included in the analysis.
clinical (anamnesis and physical examination), cytological or histo­
logical; the latter was considered to be the most valid. The certainty 
factor is a measure of the extent and reliability of the examination 
procedures used for staging [19]. If there were insufficient data on 
the tumour (T), regional lymph nodes (N) or distant metastases (M) 
in the medical file, that part of the TNM was coded CO. The cer­
tainty factor was recorded as C l when data were available from 
standard examination procedures (anamnesis, X-ray photographs), 
C2 when data were available from more advanced examination 
procedures and C3 if surgical exploration had taken place. Per type 
of cancer (except for non-Hodgkin lymphomas because no C factor 
was recorded for them) we determined the proportion of patients 
per age category in whom the stage could be determined but for 
whom one or more parts of the TNM  had a certainty factor of 0 
(CO).
Treatment
Treatment concerned the primary treatment received by the patient 
in the first three months after diagnosis, in terms of: surgery, radio­
therapy, chemotherapy, endocrine treatment, other therapy, all pos­
sible combinations of these, and no treatment. Treatment policies 
for patients with lung cancer were analysed separately for small-cell 
lung cancer and non-small-cell lung cancer patients. Because the 
distinction between small-cell and non-small-cell lung cancer is 
based on the microscopically-confirmed morphology of the tumour, 
the basis for diagnosis was not analysed separately in order to avoid 
the risk of selection bias.
An overview of regular treatment policies for the various malig­
nancies in the IKL-region was made by two clinical consultants from 
the Comprehensive Cancer Centre Limburg (HS, JJ), an internist- 
oncologist and a radiotherapist-oncologist (see Table 1).
Table I  General treatment per malignancy and stage in Middle and 
South Limburg.
The extent of the diagnostic work-up was derived from the basis for 
diagnosis and from the degree of ccrtainty about the TNM classifi­
cation (certainty factor). The basis for making the diagnosis was
Malignancy S tage Treatment
Colorectal 1, 2, 3 Surgery whether or not in combination 
with radiotherapy or chemotherapy
41 Chemotherapy or no treatment
Lung, non­ 1 ,2 ,3 Surgery or radiotherapy or a com­
small-cell bination of the two
41 No treatment
Lung, small­ Limited Chemotherapy whether or not in com­
cell bination with surgery or radiotherapy
Extensive Chemotherapy
Breast 1 ,2 ,3 Surgery whether or not in combination 
with radiotherapy or chemotherapy or 
endocrine therapy
4 a Chemotherapy or endocrine therapy
Ovary 1, 2, 3 Surgery in combination with chemo­
therapy
4“ Chemotherapy
Head-neck 1,2, 3 Surgery or radiotherapy or a combina­
tion of the two
4* Chemotherapy or no treatment
NI-IL-Iow 1 Radiotherapy
grade 2 ,3 ,4 Chemotherapy whether or not in com­
bination with radiotherapy
NHL-inter­ all Chemotherapy whether or not in com­
mediate/
high-grade
bination with radiotherapy
“ Distant metastases.
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Data analysis
For each malignancy we analysed the relationship between age and 
the extent of the diagnostic work-up, and between age and treatment 
by using the Pearson Chi-square test and the Mantel-Haenszel chi- 
square test for trend. As the treatment for cancer depends on the 
extent of the tumour, for each malignancy we also analysed the rela­
tionship between tumour stage and the age category of the patient. 
With the aid of models based on logistic regression (SAS, procedure 
LOG1ST) we evaluated the extent to which the age at diagnosis of 
each malignancy influenced the chance of not receiving treatment. 
These analyses were corrected for the effects of stage and sex.
Results
year olds versus 26% and 24% in the two other age 
categories. This was also true for colorectal cancer, 
25%, 19% and 17%, respectively. When the proportion 
of unknown stages was added, this difference tended to 
disappear for the colorectal group but only partially 
disappeared for the head and neck cancer group.
Sometimes the stage of the disease was based on less 
extensive staging examinations (certainty factor = 0 for 
T, N or M). This phenomenon was associated with in­
creasing age, although this was not statistically signifi­
cant (see Tables 2 and 3)*
Malignancy grade
General In the elderly patients with non-Hodgkin lymphomas,
malignancy grade was unknown in a larger proportion 
The total study population comprised 6911 patients than in the younger patients: 26% in the 70+ age cat- 
(3515 men and 3396 women). The percentages of men egory versus 15% and 22% in the younger age catego- 
in the lung cancer group, the head and neck tumour ries (P = 0*014). Moreover, more of the elderly patients 
group, the non-Hodgkin lymphoma group and the had a high or intermediate malignancy grade than the 
colorectal tumour group were 91%, 79%, 48% and younger patients (Table 4).
49%, respectively.
Treatment
Diagnosis
In the total study population, 16% were not treated 
The diagnosis was confirmed histologically in 88% of (n ™ 1081). Per age category 50-59 years, 60-69 years 
the total patient population. Per age category 50-59 and 70+ these percentages were 7%, 12% and 22%, 
years, 60-69 years and 70+ these percentages were respectively (P-trend = 0.001).
93%, 90% and 83%, respectively. In the patients with In 12% of the complete study population, the stage
breast, lung and colorectal cancer there was a signifi- of the tumour was unknown; 51% of these patients
cant increase in the proportion of patients without his- were not treated. Per age category 50-59 years, 60-69
tological or cytological confirmation with increasing years and 70+, these percentages were 23%, 45% and
age, but proportions were very small. For ovarian can- 58%, respectively (P-trend = 0.001), A  higher age was
cer, 14% of the diagnosis of elderly patients was based significantly associated with an unknown stage and no
on cytological grounds, while this was only 2% in the treatment. Although this applied to all malignancies,
younger age categories. Also for lung cancer, cytologi- the percentages differed to some extent per site and
cal confirmation of the diagnosis played a fairly major varied from 9%, 9% and 16% per age category in the
role. In 20% of these patients the diagnosis was con- breast cancer group to 38%, 58% and 74% in the pa-
firmed cytologically (see Table 3). In the three age cat- tients with non-small-cell lung cancer (see Tables 2, 3
egories 50-59 years, 60-69 years and 70+ years, the and 4).
diagnosis was confirmed cytologically in 16%, 17% and In the patients with stage 1, 2 or 3 at diagnosis (n -
24%, respectively (P-trend = 0.001). 4519, excluding the non-Hodgkin lymphomas), overall
5% were not treated. Per age category 50-59 years, 60- 
69 years and 70+, this was 2%, 4% and 8%, respective­
ly (P-trend “  0.001), For stage 1-3 patients there was
Classification of tumour stage per age category is wide variation in the proportions of untreated patients
shown in Tables 2, 3 and 4. For all malignancies, the per malignancy (see Tables 2 and 3), The proportion
stage was unknown in a larger proportion of the elderly was particularly high in the patients with lung cancer
patients than the younger patients. The difference was and there was an increase with increasing age (P-
statistically significant in all the malignancy groups, trend ■» 0.001). Treatment patterns showed that a single
except for non-Hodgkin lymphoma and ovarian cancer treatment modality was applied more often to the
(the two smallest groups). In the colorectal and lung elderly patients than to the younger ones; for colorectal
tumour groups, this was associated with a lower pro- cancer this was surgery, for ovarian cancer this was sur-
portion of elderly patients with more advanced stage gery or only chemotherapy, for non-small-cell lung can-
disease, whereas in the breast and ovarian cancer cer this was radiotherapy and for breast cancer this was
groups, the proportion of women with stage 4 disease surgery or endocrine therapy. In contrast, more of the
increased with increasing age. Furthermore, a relatively younger patients received combination therapy, which 
large number of young patients with advanced stage 
head and neck cancer was found: 41% in the 50-59
depended on the localisation. Particularly in the breast 
cancer group, there were many more different treat-
Table 2. Distribution according to age, stage, diagnostics and treatment for patients of 50 years and older with head and neck, breast, colorectal and ovarian cancer, IK L 1988-1992.
Age
Head-Neck
50-59 60-69 70+ Tot.
Breast
50-59 60-69 70+ Tot.
Colorectal
50-59 60-69 70+ Tot
Ovary
50-59 60-69 70+ Tot.
N I l l 163 138 412 488 552 597 1637 293 600 1042 1935 54 90 111 255
Stage
1 25% 32% 36% 31% 36% 35% 19% 29% 22% 25% 23% 23% 24% 24% 18% 22%
2 12% 15% 9% 12% 47% 48% 49% 48% 25% 28% 28% 28% 17% 12% 9% 12%
3 9% 16% 10% 12% 10% 9% 14% 11% 25% 23% 22% 22% 46% 39% 40% 41%
4 41% 26% 24% 30% 6% 6% 9% 7% 25% 19% 17% 19% 11% 20% 21% 18%
Unknown 12% 10% 22% 15% 2% 2% 9% 5% 3% 5% 11% 8% 2% 4% 9% 5%
Basis for diagnosis
Histology 100% 99% 99% 99% 98% 98% 87% 94% 99% 97% 96% 97% 96% 97% 82% 90%
Cytology 1% 1% 1% 1% 1% 10% 5% — 1% 1% 1% 2% 2% 14% 7%
Staging diagnostics2
Insufficient 6% 4% 10% 6% 3% 3% 4% 4% 4% 5% 6% 5% 6% 16% 18% 14%
Treatment stage 1-3 N 51 103 75 229 450 507 491 1448 209 454 754 1417 47 68 74 189
No treatment 2% 3% 7% 4% — — 1% 0% 2% 1% 1% 1% 2% 7% 13% 8%
Surgery (S) 29% 22% 21% 24% 17% 20% 30% 23% 81% 86% 90% 87% 19% 22% 24% 22%
Radiotherapy (RT) 49% 55% 52% 53% -------- 0% 0% 0% 0% 1% 1% 1% — — —
Chemotherapy (CT) — — — 0% 0% ------- 0% 1% — — 0% 11% 13% 19% 15%
Endocrine th. (ET) — — 1% 1% 14% 5% — — — — — —
S + RT 16% 15% 17% 16% 37% 38% 16% 31% 6% 4% 4% 4% 2% 1% 1%
S + CT — — — — 7% 3% 2% 4% 8% 6% 2% 4% 66% 54% 42% 52%
S+ET 12% 12% 27% 17% — — 0% 0% —
Other 4% 4% 3% 3% 25% 25% 10% 20% 2% 2% 2% 3% 3% 2% 2%
Treatment stage 4 N 46 43 j j 122 27 34 51 112 74 115 178 367 6 18 23 47
No treatment 6% 9% 12% 9% 3% 12% 6% 8% 17% 30% 22% 40%
6%
26%
9%
28%
8%Surgery (S) 9% 7% 9% 8% —
A  /  w V /  /  V
40% 48% 54% 50% 17%
Chemotherapy (CT) 4% J  /o 2% 18% 15% 4% 11% 11% 10% 4% 8% 33% 16% 52% 36%
Radiotherapy (RT) 33% 26% 33% 30% — -------- 2% 1% 1% 2% 1% — —
Endocrine th. (ET) — — — 26% 35% 59% 44% -------- — — ------- —
S + RT/ET/CTb 39% 51% 36% 43% 33% 23% 12% 20% 35% 20% 6% 16% 50% 38% 13% 28%
Other 9% 7% 7% 8% 23% 27% 11% 18% 5% 5% 4% 3% — — —
Treatment stage Unknown N 14 17 30 61 11 11 55 77 10 31 110 151 1 4 14 19
No treatment 7% — 13% 8% 9% 9% 16% 14% 30% 42% 61% 55% 100% 25% 50% 47%
Treatment 64% 77% 77% 74% 91% 82% 68% 73% 50% 45% 17% 32% — 75% 36% 43%
Treatment ? 29% 23% 10% 18% — 9% 16% 13% 20% 13% 12% 13% — 14% 10%
a Thoroughness of staging diagnostics, derived from the certainty factor. These percentages are only valid for the patients with a known stage* 
b S +RT for head and neck cancer; S + ET for breast cancer; S + CT for ovary' and colorectal cancer.
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Table 3. Distribution according to age, stage, diagnostics and treatment for patients of 50 years and older with lung cancer; IKL  
[992.
Age
Lung cancer (all) 
50-59 60-69 70+ Total
N 428 891 1022 2341
Basis for diagnosis
Histology 80% 78% 64% 72%
Cytology 16% 17% 24% 20%
Staging diagnostics1
Insufficient 6% 8% 9% 8%
Non-small--cell lung cancer Small-cell lung cancer
Age 50-59 60-69 70+ Total 50-59 60-69 70+ Total
N 302 688 859 1849 126 203 163 492
Stage
lb 22% 21% 18% 20% 37% 41% 35% 38%
2 6% 4% 3% 4%
3 31 % 32% 27% 29%
4h 26% 24% 19% 22% 50% 43% 42% 45%
Occult1' 4% 1% 1% 2%
Unknown 11% 18% 32% 23% 13% 16% 23% 17%
Treatment stage l- 3 h N  189 395 425 1009 56 98 73 227
No treatment 6% 10% 24% 15% 4% 11% 19% 12%
Surgery (S) 48% 41% 24% 35% 2% 2% I % 2%
Radiotherapy (RT) 27% 36% 44% 38% 2% « m u M 1 % 1 %
Chemotherapy (CT) 4% 1% 0% 1% 80% 74% 73% 75%
S + RT 13% 9% 6% 9% — — — —
RT + CT — 1% 1% 0% 7% 10% 5% 8 %
Other 2% 1 % 2% 1% 7% 3% I % 2%
Treatment stage 4 h N 79 168 162 409 63 87 69 219
No treatment 57% 55% 70% 62% 10% 16% 35°/. 20%
Chemotherapy (CT) 15% 11 % 2% 8% 82% 77% 60% 73%
Radiotherapy (RT) 16% 28% 20% 23% 2% 2% 4% 3%
Other 12% 6% 8% 7% 6% 5% 1 % 4%
Treatment stage unknown N 34 125 272 431 7 18 21 46
No treatment 38% 58% 74% 67% 14% 22% 52% 35%
RT/CTd 35% 26% 16% 21 % 86% 57% 29% 48%
Other 27% 16% 10% 12% 11 % 19% 17%
a Thoroughness of staging diagnostics, derived from the certainty factor. These percentages are only valid for the patients with a known 
stage.
l) The stage of small-cell lung carcinoma is coded according to ‘extend of disease’. Limited disease stage 1, extensive disease -* stage 4. 
c Occult stage: the primary tumour could not be evaluated, or the presence of a tumour was detected through malignant cells in sputum or 
bronchial rinsing, but was not visible on a chest X-ray or at bronchoscopy (TX, NO, MO). For analysis these patients were classified under 
stage 1.
ll Radiotherapy for non-small-cell lung cancer; chemotherapy for small-cell lung cancer.
ment combinations in the younger patients than in the in combination with surgery. The younger patients were
70+age category given more often a combination of surgery and chemo-
In the total group of patients with metastatic cancer therapy than the elderly (see Table 2). The vast major- 
(n = 1126 excluding the non-Hodgkin lymphomas), ity (94%) of patients with metastatic breast cancer re- 
36% were not treated. Per age category 50-59 years, ceived treatment, which usually comprised endocrine 
60-69 years and 70+, this was 20%, 30% and 40%, therapy (44%) or a combination of surgery and endo- 
respectively (P-trend = 0.001). About 38% of the pa- crine therapy (20%); however, more of the elderly 
tients with a metastatic non-small cell lung tumour women only received endocrine therapy than the 
were treated, mainly with radiotherapy (23%). This dif- younger ones. Nearly all of the patients with metastatic 
fered substantially from the percentage with a small cell head and neck cancer were treated (91%). They re­
tumour: 80% received treatment, mainly chemotherapy ceived surgery and radiotherapy (43%) or only radio- 
(73%). For the patients with stage 4 ovarian cancer it therapy (30%); this also applied to the elderly patients, 
was found that a remarkable high proportion of pa- Furthermore, it was found that in the patients with a 
tients received chemotherapy (64%), from which 28% metastatic colorectal tumour, more of the women aged
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Table 4. Distribution according to age, stage, diagnostics and treat­
ment for patients of 50 years and older with a non-Hodgkin lym 
phoma. IKL, 1988-1992.
Non-Hodgkin lymphoma
Age 50-59 60-69 70+ Total
N 74 105 152 331
Basis for diagnosis
Histology 97% 94% 94% 95%
Cytology 3% 6% 6% 5%
Stage (Ann Arbor)
1 28% 36% 26% 30%
2 24% 17% 17% 18%
3 11 % 15% 18% 16%
4 24% 25% 22% 24%
Unknown 12% 7% 16% 12%
Malignancy grade
Low 27% 15% 10% 15%
Intermediate 57% 60% 59% 59%
High 1% 3% 5% 4%
Not classified 15% 22% 26% 22%
Treatment stage 1 N 21 38 40 99
No treatment — — 13% 5%
Surgery (S) 14% 24% 22% 21%
Radiotherapy (RT) 5% 13% 35% 20%
Chemotherapy (CT) 19% 29% 12% 20%
S + RT 9% 16% 2% 9%
S + CT 14% 8% 7% 9%
R T + C T 24% 8% 5% 10%
Other 15% 2% 4% 6%
Treatment stage 2-4 N 44 60 87 191
No treatment 4% 7% 16% 10%
Chemotherapy (CT) 77% 75% 57% 67%
C T + R T 4% 5% 8% 6%
Other 15% 13% 19% 17%
Treatment stage unknown N 9 7 25 41
No treatment — 14% 28% 19%
Treatment 22% 29% 36% 32%
Treatment ? 78% 57% 36% 49%
70+ years did not receive treatment than the men with­
in this age category, 40% and 21%, respectively. Other­
wise no sex differences were found.
The elderly patients with a non-Hodgkin lymphoma 
stage I received radiotherapy (35%), surgery (22%) or 
chemotherapy (12%), while the younger patients re­
ceived more often a combination of these treatments 
(see Table 4).
The majority of patients with a non-Hodgkin lym­
phoma stage 2, 3 or 4 received chemotherapy, but the 
percentage decreased with increasing age. In the three 
age categories 50-59 years, 60-69 years and 70+, the 
percentages were 77%, 75% and 57%, respectively 
(jP** 0.023). When the malignancy grade was also in­
cluded in the analysis (data not shown), we found that 
only 10% of the patients with low grade disease, stage 1 
(n =* 11), received radiotherapy alone, whereas this per­
centage was 45% in the patients with intermediate or 
high grade disease. In the patients with low grade dis­
ease, stage 2, 3 or 4, 50% received chemotherapy and 
18% were not treated, whereas 74% of the patients with 
intermediate or high grade disease, stage 2 , 3 or 4 re­
ceived chemotherapy and 7% were not treated. The
majority of patients who were not treated were 70 years 
of age or older.
The logistic regression analyses showed that, cor­
rected for stage and sex, the chance of not receiving 
treatment increased with increasing age (see Table 5). 
In the colorectal cancer group, the effect of higher age 
depended on the tumour stage and the sex of the pa­
tient (see Table 6). The effect of age on the chance of 
not being treated was greater for women of 70 years 
and older than for men. Owing to the fact that nearly all 
of the breast cancer patients were treated, we investi­
gated the effect of age on the chance of receiving one
Table 5, Odds ratios and 95% confidence intervals for no treatment 
according to age, adjusted for stage and sex, Various sites, age: 50
years and older, IKL, 1988- 1992,
Site Age Treatment Odds ratio
95% Clb
No Yes
Head-neck 50-59 5 106 l b
60-69 7 156 1.0 (0.3-3.4)
70+ 13 '125 2.7 (0.9-7.9)
Lung, small cell 50-59 9 117 l 1
60-69 29 174 2,2 (0.9-4.8)
70+ 49 114 5.5 (2.6-11,9)
Lung, non-small cell 50-59 70 232 lb
60-69 206 482 1.4(1,0-2.0)
70+ 418 441 3.2 (2.2-4.5)
Ovary 50-59 2 52 l h
60-69 13 77 3.7 (0.8-17.5)
70+ 23 88 4.7 (1.1-21.4)
Non-Hodgkin lymphoma 50-59 2 72 l h
60-69 5 100 1,8 (0.3-9.5)
70+ 26 126 7,4(1.7-32.2)
a 95% confidence interval, 
h Reference category,
Table 6. Odds ratios and 95% confidence intervals for no treatment 
according to age; patients with colorectal cancer aged 50 years and 
older. IKL 1988-1992,
Colo ree tal
Sex Treatment Odds ratio
95% C lb
No Yes
Age
50-59 13 280 l c
60-69“ 39 561 1.6 (0,8-3.3)
Age + stage1
70+ stage 1-3 Men 2 346 0.8 (0,3-2,5)
Worn en 7 399 1.4 (0.5-4.1)
70+ stage 4 Men 19 71 2,8 (1.2-6.3)
Women 35 53 4.8 (1.7-10.7)
70+ stage Men 30 23 2.7 (1.0-7.0)
unknown Women 37 20 4,6 (1.7-12.6)
“ Adjusted for stage and sex.
95% confidence interval.
0 Reference category,
(i The effect of age 70+ was different for men and women and 
depended on stage. Therefore, the odds ratios are presented sepa­
rately.
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treatment modality versus a combination of two or Lung cancer on the contrary, revealed large age-spe-
Table 7. Odds ratios and 95% confidence intervals for one treat­
ment modality versus two or more treatment modalities according to 
age; breast cancer, age 50 years and older. IK L  1988-1992.
more modalities. The results showed that a higher age cific differences in the diagnostic work-up and treat- 
at diagnosis increased the chance of only receiving one ment methods. This was probably related with the fact 
type of treatment (see Table 7). that lung cancer still has a very poor prognosis. For
example with non-metastatic non-small-cell lung can­
cer, older age decreased the likelihood of receiving sur­
gery: 61% of the patients in the age category 50-59 
years were operated on, while this was 50% in the 60- 
69 year olds and only 30% in those of 70+ years. A 
reluctancy to operate on elderly patients was described 
earlier by Smith et al, [21] for locoregional NSCLC. 
They studied differences in treatment patterns of lung 
cancer with data from incident cases from the Virginia 
Cancer Registry, 1985-1989. In their study comorbid­
ity did not appear to have influence. However, over the 
past few years, various authors have argued in favour of 
considering tumour resection in elderly patients with a 
non-small cell lung carcinoma [15, 22],
For breast and ovarian cancer, the total of stage 4 
and stage unknown is much higher in elderly patients, 
which may indicate patient delay, A  high percentage of 
Age-specific differences in the diagnostics and treat- elderly patients with advanced stage disease is in 
ment of patients with various forms of cancer, diag- agreement with some studies [6 , 23, 24] but not with 
nosed in the period 1988-1992, were investigated* other [25, 26]. Especially for breast cancer the litera- 
Data on incident cancer cases and data on diagnostic ture on the age-stage relationship is inconsistent [27].
Site Age Treatment Odds ratio
95% CP
One >O ne
Breast 50-59 1 01 387 l h
60-69 133 419 1.3 (0,9-1.6 )
70+ 277 320 3.4 (2.Ó-4.5)
H 95% confidence interval, 
b Reference category.
Discussion
procedures and treatment were obtained from the Since the end of the 1980s, it was recommended not
population-based Regional Cancer Registry Limburg, to treat elderly breast cancer patients with endocrine
Several findings indicated that elderly patients had therapy alone (usually Tamoxifen) [6 , 28—30]. This
undergone a less extensive diagnostic work-up: a larger policy was also recommended in our region and we
proportion of unknown tumour stage among the elder- found that a considerable proportion of the elderly
ly, a higher proportion of patients without a histologi- patients received a combination of surgery and endo-
cally or cytologically confirmed diagnosis, and a higher crine therapy: 27% for stage 1-3 patients and 12% for
proportion of patients in whom the stage was based on stage 4 patients. However, 14% of the elderly patients
less accurate diagnostic procedures (certainty factor), with breast cancer stage 1-3 and 59% of the elderly
Furthermore, it could be concluded that a higher age patients with advanced stage disease received endo-
increased the chance of not being treated or of receiv- crine therapy alone.
ing less intensive treatment. In the elderly patients with a metastatic colorectal
The extent of the diagnostic work-up was derived tumour (// «  178), more elderly women than elderly 
from the basis for diagnosis and from the degree of cer- men did not receive treatment, 40% and 21%, rcspec- 
tainty about the TNM classification (certainty factor), tively, which is in agreement of earlier findings |8|. 
Our classification according to the certainty factor was However, within this wide age category the average age 
rather rigorous and may have caused some misclassifi- of the women was higher than that of the men. Pro lo­
cation. For example, a lung tumour which had a CO for ably there was also more comorbid disease among the 
M, but C2 for T and C2 for N, which can be enough elderly women.
information to make the decision not to operate, was One of the factors that is of great importance for the
valued in this study as being insufficient diagnostic prognosis of a patient with a non-Hodgkin lymphoma 
work-up. Also a rather high proportion of the certainty is the malignancy grade. In this study we found that
22% of the NHL patients could not be classified, Partly 
this was due to the fact that the diagnosis was based
factor was missing for one or more parts of the TNM.
Nevertheless, an association was found between the 
diagnostic work-up according to the certainty factor upon cytology only. Also, there is no classification 
and age, suggesting a less extensive work-up at higher according to the Working Formulation for a group of 
age.
The degree to which diagnostics and treatments dif­
fered and the nature of these differences depended on 
the localisation of the tumour. For head and neck can-
lymphomas which comprise 5% of the total of lympho­
mas (e.g., T-cell lymphoma). However, these two phe­
nomena do not completely explain the high proportion 
of unclassified lymphomas, which may be partially due
cer, for example, there were hardly any age-specific dif- to a registration artefact. Furthermore, we had to be 
ferences in the treatment modalities applied. It is pos- cautious with our analyses on this patient group, 
sible that the heterogeneity within this group of because stratifying the patients according to stage,
tumours obscured any differences. malignancy grade and age sometimes produced very
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